What options may exist if GLP-1 coverage through commercial insurance ends during treatment?

If GLP-1 insurance coverage ends, options include appealing the decision, applying for manufacturer savings programs, or exploring physician-supervised compounded options.

Understanding Why GLP-1 Coverage Changes

Annual formulary updates are a primary reason for losing GLP-1 coverage. Insurance plans review their list of covered drugs (formulary) each year and may remove certain medications, move them to a higher-cost tier, or add new restrictions.

A change in employment status or your employer switching insurance providers can lead to a new health plan with different coverage rules. This new formulary may not cover your current GLP-1 medication, interrupting your treatment.

Prior authorization (PA) requirements can also change. Your plan might suddenly require a new PA or deny a renewal request if they determine you no longer meet their specific criteria for medical necessity, even if your physician disagrees.

Some plans impose "step therapy," requiring you to try and fail on less expensive alternatives before they will approve a GLP-1 agonist. If this policy is introduced mid-treatment, your coverage for your current medication could be stopped until the new requirements are met.

Appealing the Insurance Decision

Your first step should be to formally appeal the coverage denial. Insurance providers are legally required to have a clear appeals process. You can typically initiate this by calling the member services number on your insurance card or through their online portal.

Ask your physician to submit a letter of medical necessity on your behalf. This letter should detail your treatment history, the medication's effectiveness for you, and the clinical reasoning for why continued treatment is essential for managing your health.

Your doctor can also request a formulary exception or a peer-to-peer review. A formulary exception is a formal request to cover a non-preferred drug, while a peer-to-peer review allows your doctor to discuss your case directly with a medical reviewer from the insurance company.

Manufacturer Savings and Assistance Programs

Drug manufacturers offer savings cards that can significantly reduce co-pays for patients with commercial insurance. Eli Lilly provides cards for Zepbound and Mounjaro, while Novo Nordisk offers them for Wegovy and Ozempic. These can lower monthly costs to as little as $25 for eligible patients.

These savings cards are generally not usable if you are uninsured or have government-sponsored insurance like Medicare or Medicaid. They are designed to lower the out-of-pocket cost for patients whose commercial plan covers the drug but has a high deductible or co-pay.

For uninsured or low-income individuals, manufacturers may have Patient Assistance Programs (PAPs). The NovoCare Patient Assistance Program and the Lilly Cares Foundation are examples that may provide medication at little to no cost for those who meet specific income and eligibility criteria.

Physician-Supervised Compounded Medications

During drug shortages, as listed by the FDA, compounding pharmacies may be permitted to prepare medications containing the same active ingredients as branded GLP-1s, such as semaglutide or tirzepatide. These are prescribed by a physician based on an individual's medical needs.

It is critical to understand that compounded medications are not FDA-approved. They have not undergone the same rigorous safety, efficacy, or manufacturing reviews as branded drugs like Wegovy or Zepbound. You should only use medications prepared by licensed U.S. pharmacies under a doctor's care.

GOAL.MD offers physician-supervised programs that may include compounded semaglutide with B12 (starting at $299/month) or tirzepatide with B12 (starting at $449/month). These are prescribed as part of a comprehensive [weight loss](/weight-loss) program following a telehealth consultation.

These programs can provide a continuity option when insurance coverage is lost or branded medications are unaffordable, allowing patients to continue treatment with medical oversight without relying on insurance approval.

Bottom Line: Navigating a Loss of Coverage

Losing insurance coverage for a GLP-1 medication can be disruptive, but several pathways exist. Start by working with your doctor to file a formal appeal with your insurance company, as this is the most direct route to potentially restoring coverage.

Concurrently, investigate manufacturer programs. If you still have commercial insurance but face a high co-pay, a savings card may be the solution. If you are now uninsured, check the income and eligibility requirements for Patient Assistance Programs (PAPs).

If appeals fail and manufacturer programs are not an option, discussing physician-supervised compounded medications can be a viable next step. Ensure any such program involves a licensed physician and a reputable, U.S.-based pharmacy for your safety.

This article is for informational purposes only and does not constitute medical advice.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.